RT Journal Article
T1 New highlights of resveratrol: a review of properties against ocular diseases
A1 Delmas, Dominique
A1 Cornebise, Clarisse
A1 Courtaut, Flavie
A1 Xiao , Jianbo
A1 Aires, Virginie
K1 3201.09 Oftalmología
K1 3309.20 Propiedades de Los Alimentos
K1 2302 Bioquímica
AB Eye diseases are currently a major public health concern due to the growing number of cases resulting from both an aging of populations and exogenous factors linked to our lifestyles. Thus, many treatments including surgical pharmacological approaches have emerged, and special attention has been paid to prevention, where diet plays a preponderant role. Recently, potential antioxidants such as resveratrol have received much attention as potential tools against various ocular diseases. In this review, we focus on the mechanisms of resveratrol against ocular diseases, in particular age-related macular degeneration, glaucoma, cataract, diabetic retinopathy, and vitreoretinopathy. We analyze, in relation to the different steps of each disease, the resveratrol properties at multiple levels, such as cellular and molecular signaling as well as physiological effects. We show and discuss the relationship to reactive oxygen species, the regulation of inflammatory process, and how resveratrol can prevent ocular diseases through a potential epigenetic action by the activation of sirtuin-1. Lastly, various new forms of resveratrol delivery are emerging at the same time as some clinical trials are raising more questions about the future of resveratrol as a potential tool for prevention or in therapeutic strategies against ocular diseases. More preclinical studies are required to provide further insights into RSV’s potential adjuvant activity.
PB International Journal of Molecular Sciences
SN 14220067
YR 2021
FD 2021-01-28
LK http://hdl.handle.net/11093/4061
UL http://hdl.handle.net/11093/4061
LA eng
NO International Journal of Molecular Sciences, 22(3): 1295 (2021)
NO Agence Nationale de la Recherche, France | Ref. ANR-11-LABX-0021
DS Investigo
RD 16-sep-2024